Drug Profile
Interferon beta-1a biosimilar - CinnaGen
Alternative Names: CinnoVex; Rec Hu - IFN beta1aLatest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator CinnaGen
- Class Antiasthmatics; Antineoplastics; Antivirals; Interferons; Vascular disorder therapies
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Multiple sclerosis
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for phase-I development in Multiple-sclerosis(In volunteers) in Finland (IM, Injection)
- 12 Feb 2019 Cinnagen completes phase I trial in Multiple Sclerosis (In volunteers) in Finland (NCT03614715)
- 22 Feb 2018 CinnaGen initiates a phase III trial for Multiple sclerosis in Iran (IM) (IRCT201612306135N8)